Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator

The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.